Marc Le Borgne

Prof. Marc Le Borgne

Université Claude Bernard Lyon1
+1
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
SISamar Issa
Samar Issa
APAnthony Prandina
Anthony Prandina
NBNicolas Bedel
Nicolas Bedel
PRPål Rongved
Pål Rongved
SYSaïd Yous
Saïd Yous
ZBZouhair Bouaziz
Zouhair Bouaziz
For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic-carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.

15 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAlexandre Bancet
Alexandre Bancet
CRClaire Raingeval
Claire Raingeval
Thierry LombergetThierry Lomberget
Thierry Lomberget
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
JGJean-francois Guichou
Jean-francois Guichou
IKIsabelle Krimm
Isabelle Krimm

18 December 2020 in Crystals
Verified
Journal Article
Open access
PDF file
ASAlina Sakalauskiene
Alina Sakalauskiene
CJChristine Janssen
Christine Janssen
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
BGBrigitte GROSGOGEAT
Brigitte GROSGOGEAT
During the 20th century, metal alloys have assumed an important role as restorative materials. Among existing examples, cobalt–chromium (Co–Cr) alloys increasingly began to be used in medicine and especially in dentistry. Their success is mainly due to their mechanical properties such as stiffness, strength and corrosion resistance, thus allowing a high biocompatibility. There are quite meaningful data on the corrosion and toxicity of Co–Cr alloys for their use in restorative materials such as dental prostheses. Toxicological studies following Co and Cr exposures in the oral cavity are more difficult to conduct because there are many different situations leading to the release of metal ions and wear particles. Furthermore, the links between exposure and the appearance of local or systemic toxicity are not automatic. Since 2017, the European Union (EU) regulatory framework for Co–Cr alloys has been undergoing profound changes. A new EU Medical Devices Regulation (MDR) (2017/745) will be applied in May 2021 with the need to consider that Co metal is a new carcinogenic, mutagenic and toxic to reproduction (CMR) substance. On 18 February 2020, the 14th Adaptation to Technical Progress (ATP14) to the Classification, Labelling and Packaging (CLP) regulation was published, including the harmonised classification for Co metal as a CMR 1B substance. In this context, the use of Co might be forbidden if the medical devices are invasive and as soon as they include more than 0.1% (m/m) Co. This review provides a specific overview on Co–Cr dental alloys in terms of metal ions and wear particles release, toxicological risks, and the actual and new EU regulatory framework.

1 July 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Jean GuillonJean Guillon
Jean Guillon
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
CRCharlotte Rimbault
Charlotte Rimbault
SMStéphane Moreau
Stéphane Moreau
SSSolène Savrimoutou
Solène Savrimoutou
Joachim JoseJoachim Jose
Joachim Jose
Herein we describe the synthesis and properties of substituted phenylaminopyrrolo[1,2-a]quinoxaline-carboxylic acid derivatives as a novel class of potent inhibitors of the human protein kinase CK2. A set of 15 compounds was designed and synthesized using convenient and straightforward synthesis protocols. The compounds were tested for inhibition of human protein kinase CK2, which is a potential drug target for many diseases including inflammatory disorders and cancer. New inhibitors with IC50 in the micro- and sub-micromolar range were identified. The most promising compound, the 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-3-carboxylic acid 1c inhibited human CK2 with an IC50 of 49 nM. Our findings indicate that pyrrolo[1,2-a]quinoxalines are a promising starting scaffold for further development and optimization of human protein kinase CK2 inhibitors.

1 April 2012 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CHClaas Hundsdörfer
Claas Hundsdörfer
HHHans-Jörg Hemmerling
Hans-Jörg Hemmerling
CGClaudia Götz
Claudia Götz
FTFrank Totzke
Frank Totzke
Patrick J. BednarskiPatrick J. Bednarski
Patrick J. Bednarski
Joachim JoseJoachim Jose
Joachim Jose

16 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GGGustavo Jabor Gozzi
Gustavo Jabor Gozzi
ZBZouhair Bouaziz
Zouhair Bouaziz
EWEvelyn Winter
Evelyn Winter
NDNathalia Daflon-Yunes
Nathalia Daflon-Yunes
DADagmar Aichele
Dagmar Aichele
APAttilio Di Pietro
Attilio Di Pietro